Protagenic Therapeutics, Inc.\new (PTIX) intrinsic value & 10-year financials
Protagenic Therapeutics, Inc.\new (PTIX) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue reached to $0, with an average return on invested capital of -49.8%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.76
- Market cap
- $3.7M
- Revenue (FY2024)
- $0
- ROIC (10-yr avg)
- -49.8%
- Free cash flow (FY2024)
- —
PTIX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2024 | $0 | -$5.5M | -$1.13 | — | — | -236.1% |
| FY2023 | $0 | -$5.0M | -$1.15 | -$3.9M | — | -94.5% |
| FY2022 | $0 | -$3.6M | -$0.82 | -$2.0M | — | -42.2% |
| FY2021 | $0 | -$4.5M | — | — | — | -102.9% |
| FY2020 | $0 | -$2.5M | — | — | — | 285.7% |
| FY2019 | — | -$1.8M | — | — | — | 414.3% |
| FY2018 | — | -$2.6M | — | — | — | -507.2% |
| FY2017 | — | -$2.3M | — | — | — | -122.3% |
| FY2016 | $0 | -$2.3M | — | — | — | -246.8% |
| FY2015 | $0 | -$1.0M | — | -$383.1K | — | 153.6% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Protagenic Therapeutics, Inc.new revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Protagenic Therapeutics, Inc.new has historically struggled to out-earn its cost of capital, averaging just -36.3% ROIC.
Protagenic Therapeutics, Inc.new capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Protagenic Therapeutics, Inc.new is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.